RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute

Drug Profile

RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Bio Farma Indonesia; Murdoch Childrens Research Institute
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Rotavirus infections

Most Recent Events

  • 21 Sep 2016 Bio Farma completes a phase-II clinical trial in Rotavirus infections (In neonates) in Indonesia (PO) (ACTRN12612001282875)
  • 18 Jul 2016 Bio Farma announces intention to submit application for Licensure to Badan Pengawas Obat dan Makanan Republik in Indonesia
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rotavirus-infections(In adolescents, In children, In neonates, In adults) in Australia (PO, Drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top